Related Experiment Video
Updated: Jan 12, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
Novel Dimeric Capsid Assembly Modulators as a Unique Class of Highly Potent Anti-HBV Agents
Franck Amblard1, Zhe Chen1, Kalouna Kra2,3
1Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, and Children's Healthcare of Atlanta, Atlanta, Georgia 30322, United States.
New dimeric capsid assembly modulators (D-CAMs) show promise for treating chronic hepatitis B virus (HBV) infection. D-CAM-14 demonstrated enhanced potency and unique effects on HBV capsid assembly compared to existing therapies.
Area of Science:
- Hepatology
- Virology
- Drug Discovery
Background:
- Chronic hepatitis B virus (HBV) infection affects 250 million globally, leading to severe liver diseases.
- Current treatments for chronic HBV do not offer a cure, necessitating lifelong therapy.
- HBV capsid assembly modulators (CAMs) represent a novel therapeutic strategy by inhibiting viral replication.
Purpose of the Study:
- To design and evaluate novel dimeric HBV capsid assembly modulators (D-CAMs).
- To compare the potency and mechanism of action of D-CAMs against monomeric CAMs.
- To identify D-CAMs with improved efficacy for HBV treatment.
Main Methods:
- Synthesis and characterization of novel dimeric capsid assembly modulators (D-CAMs).
- In vitro evaluation of D-CAM potency and mechanism of action.
- Comparative analysis with established monomeric CAMs, such as GLP-26.
Main Results:
- D-CAM-14 exhibited significantly improved potency compared to the monomeric CAM GLP-26.
- D-CAM-14 demonstrated a unique impact on HBV capsid morphology.
- Novel kinetic assembly effects were observed with D-CAM-14.
Conclusions:
- Dimeric CAMs, particularly D-CAM-14, represent a promising advancement in HBV therapy.
- The enhanced potency and unique mechanism of D-CAM-14 warrant further investigation for clinical application.
- These findings offer a potential new avenue for developing curative HBV treatments.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
12:57Alternative In Vitro Methods for the Determination of Viral Capsid Structural Integrity
Published on: November 16, 2017
Related Concept Videos
Viral Structure
Viruses with RNA Genomes
Subviral Agents